Korea Post Marketing Surveillance (PMS) Study of Vizimpro

NCT04721106

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Lung Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
19 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Vizimpro® naïve patients to whom Vizimpro® can be prescribed as per the local labeling (the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations

2. Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Patients meeting any of the following criteria will not be included in the study:


1. Patients to whom Vizimpro® is contraindicated as per the local labeling. A.
Hypersensitivity to the active substance or to any of the excipients of this product.


B. This medicinal product contains lactose. Patients with rare hereditary conditions
of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
should not take this medicinal product.


2. Any patients (or a legally acceptable representative) who does not agree that Pfizer
and companies working with Pfizer use his/her information.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Lung NeoplasmsKorea Post Marketing Surveillance (PMS) Study of Vizimpro
NCT04721106
ALL GENDERS
19 Years+
years
MULTIPLE SITES
Lung NeoplasmsA Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
NCT00050830
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Greenbrae, California
  5. San Fransisco, California
  6. San Mateo, California
  7. San Pablo, California
  8. Tampa, Florida
  9. Chicago, Illinois
  10. Chicago, Illinois
  11. Park Ridge, Illinois
  12. Skokie, Illinois
  13. Jefferson, Indiana
  14. Crestview Hills, Kentucky
  15. LaGrange, Kentucky
  16. Louisville, Kentucky
  17. Louisville, Kentucky
  18. Louisville, Kentucky
  19. Boston, Massachusetts
  20. Boston, Massachusetts
  21. Ann Arbor, Michigan
  22. Ann Arbor, Michigan
  23. New York, New York
  24. Durham, North Carolina
  25. Cincinnati, Ohio
  26. Cincinnati, Ohio
  27. Cincinnati, Ohio
  28. Columbus, Ohio
  29. Philadelphia, Pennsylvania
  30. Nashville, Tennessee
  31. Nashville, Tennessee
  32. Houston, Texas
  33. Salt Lake City, Utah
  34. Chippewa Falls, Wisconsin
  35. Eau Claire, Wisconsin
  36. Ladysmith, Wisconsin
  37. Marshfield, Wisconsin
  38. Marshfield, Wisconsin
  39. Minocqua, Wisconsin
  40. Rice Lake, Wisconsin
  41. Stevens Point, Wisconsin
  42. Wausau, Wisconsin
  43. Wisconsin Rapids, Wisconsin
  44. Woodruff, Wisconsin
  45. Edmonton, Alberta
  46. Montreal, Quebec
  47. Gauting,
  48. Grosshansdorf,
  49. Heidelberg,
  50. Cork,
  51. Dublin,
  52. Bologna,
  53. Orbassano (Torino),
  54. Amsterdam, NH
  55. Hospitalet de Llobregat, Barcelona
  56. Glasgow,
  57. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Lung NeoplasmsA Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
NCT00074854
  1. Greenbrae, California
  2. San Mateo, California
  3. San Pablo, California
  4. Tampa, Florida
  5. Covington, Louisiana
  6. Metairie, Louisiana
  7. Metairie, Louisiana
  8. New Orleans, Louisiana
  9. Boston, Massachusetts
  10. Stony Brook, New York
  11. Philadelphia, Pennsylvania
  12. Gallatin, Tennessee
  13. Hermitage, Tennessee
  14. Lebanon, Tennessee
  15. Murfreesboro, Tennessee
  16. Nashville, Tennessee
  17. Nashville, Tennessee
  18. Nashville, Tennessee
  19. Nashville, Tennessee
  20. Smyrna, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Lung NeoplasmsA Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
NCT00090701
  1. Poway, California
  2. Washington, District of Columbia
  3. Tampa, Florida
  4. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Official Title A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro(Registered)
Brief Summary Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Vizimpro after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will be observed.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients to whom Vizimpro can be prescribed as per the local labeling (the first-line treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor EGFR-activating mutations
Condition Lung Neoplasms
Intervention Drug: Vizimpro
treatment group
Study Groups/Cohorts Vizimpro treatment group
This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
Intervention: Drug: Vizimpro
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: January 27, 2021)
1200
Original Estimated Enrollment
 (submitted: January 20, 2021)
300
Estimated Study Completion Date March 30, 2026
Estimated Primary Completion Date March 1, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Vizimpro® naïve patients to whom Vizimpro® can be prescribed as per the local labeling (the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations
  2. Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion criteria

Patients meeting any of the following criteria will not be included in the study:

  1. Patients to whom Vizimpro® is contraindicated as per the local labeling. A. Hypersensitivity to the active substance or to any of the excipients of this product.

    B. This medicinal product contains lactose. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.

  2. Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information.
Sex/Gender
Sexes Eligible for Study:All
Ages 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT04721106
Other Study ID Numbers A7471060
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2021